American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003David G. Pfister, Mark R. Somerfield, David H. Johnson et al.|Journal of Clinical Oncology|2003Cited by 1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Emily Howe et al.|Clinical Cancer Research|2016Cited by 1.2k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerChristopher G. Azzoli, Giuseppe Giaccone, Sherman Baker et al.|Journal of Clinical Oncology|2009Cited by 913
Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapyAnna F. Farago, Alice T. Shaw, Benjamin J. Drapkin et al.|Cancer Research|2017Cited by 9
Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).Anna F. Farago, Alice T. Shaw, Daniel A. Haber et al.|Journal of Clinical Oncology|2018Cited by 8